EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ANNUAL VIRTUALCONGRESS ESMO 2020
![EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ANNUAL VIRTUALCONGRESS ESMO 2020](/images/conferences/european-society-for-medical-oncology-annual-virtualcongress-esmo-2020_20200922151149_big.jpeg)
Programme du congrès
Lieu : Online
Pays : Espagne
Langue : ENG
Date de début :
Date de fin :
https://www.esmo.org/Conferences/ESMO-Congress-2020
Spécialités : Oncologie
ESMO 2020 Satellite Symposium: Philip Jermann - NTRK, RET and other fusion biomarkers testing
![ESMO 2020 Satellite Symposium: Philip Jermann - NTRK, RET and other fusion biomarkers testing ESMO 2020 Satellite Symposium: Philip Jermann - NTRK, RET and other fusion biomarkers testing](/images/videos/esmo-2020-satellite-symposium-philip-jermann-ntrk-ret-and-other-fusion-biomarkers-testing_20200915170120.png)
- Date : 15/09/2020
- 2 0
ESMO 2020 Highlights on durability of clinical benefit and biomarkers with AMG510 in NSCLC
![ESMO 2020 Highlights on durability of clinical benefit and biomarkers with AMG510 in NSCLC ESMO 2020 Highlights on durability of clinical benefit and biomarkers with AMG510 in NSCLC](/images/videos/esmo-2020-highlights-on-durability-of-clinical-benefit-and-biomarkers-with-amg510-in-nsclc_20200922160715.png)
- Date : 19/09/2020
- 2 0
ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study
![ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study](/images/videos/esmo-2020-highlights-on-1st-line-durvalumab-and-tremelimumab-for-mpdac-the-pa-7-study_20200922160740.png)
- Date : 19/09/2020
- 2 0
ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study
![ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study](/images/videos/esmo-2020-highlights-on-nivolumab-cabozantinib-as-1st-line-therapy-for-arcc-the-checkmate-9er-study_20200922160804.png)
- Date : 19/09/2020
- 2 0
ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study
![ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study](/images/videos/esmo-2020-highlights-on-pembrolizumab-as-1st-line-therapy-for-auc-the-keynote-361-study_20200922161205.png)
- Date : 19/09/2020
- 2 0
ESMO 2020 Highlights on neoadjuvant mFOLFIRINOX for T3-4 rectal cancer: The PRODIGE 23 study
![ESMO 2020 Highlights on neoadjuvant mFOLFIRINOX for T3-4 rectal cancer: The PRODIGE 23 study ESMO 2020 Highlights on neoadjuvant mFOLFIRINOX for T3-4 rectal cancer: The PRODIGE 23 study](/images/videos/esmo-2020-highlights-on-neoadjuvant-mfolfirinox-for-t3-4-rectal-cancer-the-prodige-23-study_20200922161325.png)
- Date : 19/09/2020
- 2 0
ESMO Virtual Congress 2020: anticipations on practice-changing results in gastric cancers
![ESMO Virtual Congress 2020: anticipations on practice-changing results in gastric cancers ESMO Virtual Congress 2020: anticipations on practice-changing results in gastric cancers](/images/videos/esmo-virtual-congress-2020-anticipations-on-practice-changing-results-in-gastric-cancers_20200922161353.png)
- Date : 19/09/2020
- 2 0
ESMO 2020 Satellite Symposium Philip Jermann talk: Genomic profiling is driving the precision
![ESMO 2020 Satellite Symposium Philip Jermann talk: Genomic profiling is driving the precision ESMO 2020 Satellite Symposium Philip Jermann talk: Genomic profiling is driving the precision](/images/videos/esmo-2020-satellite-symposium-philip-jermann-talk-genomic-profiling-is-driving-the-precision_20200915170107.png)
- Date : 15/09/2020
- 1 0
ESMO 2020 Gabriela Fernandes talk: Lung cancer diagnostic test needs: perspective from a thoracic
![ESMO 2020 Gabriela Fernandes talk: Lung cancer diagnostic test needs: perspective from a thoracic ESMO 2020 Gabriela Fernandes talk: Lung cancer diagnostic test needs: perspective from a thoracic](/images/videos/esmo-2020-gabriela-fernandes-talk-lung-cancer-diagnostic-test-needs-perspective-from-a-thoracic_20200915170131.png)
- Date : 15/09/2020
- 1 0
ESMO 2020 Highlights on blocking PI3K/AKT signalling pathway in mCRPC: The IPATential150 study
![ESMO 2020 Highlights on blocking PI3K/AKT signalling pathway in mCRPC: The IPATential150 study ESMO 2020 Highlights on blocking PI3K/AKT signalling pathway in mCRPC: The IPATential150 study](/images/videos/esmo-2020-highlights-on-blocking-pi3k-akt-signalling-pathway-in-mcrpc-the-ipatential150-study_20200922160659.png)
- Date : 19/09/2020
- 1 0
ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005
![ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005 ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005](/images/videos/esmo-2020-highlights-on-lenvatinib-plus-pembrolizumab-in-advanced-solid-tumours-leap-005_20200922160728.png)
- Date : 19/09/2020
- 1 0
ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA study
![ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA study ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA study](/images/videos/esmo-2020-highlights-on-adjuvant-osimertinib-for-egfr-mutated-nsclc-the-adaura-study_20200922160816.png)
- Date : 19/09/2020
- 1 0
ESMO W4O Roundtable: Has the COVID-19 pandemic exacerbated gender inequalities?
![ESMO W4O Roundtable: Has the COVID-19 pandemic exacerbated gender inequalities? ESMO W4O Roundtable: Has the COVID-19 pandemic exacerbated gender inequalities?](/images/videos/esmo-w4o-roundtable-has-the-covid-19-pandemic-exacerbated-gender-inequalities_20200922160634.png)
- Date : 19/09/2020
- 0 0
ESMO 2020 Highlights on alpelisib plus fulvestrant for HR+/HER2 ABC: The SOLAR-1 study
![ESMO 2020 Highlights on alpelisib plus fulvestrant for HR+/HER2 ABC: The SOLAR-1 study ESMO 2020 Highlights on alpelisib plus fulvestrant for HR+/HER2 ABC: The SOLAR-1 study](/images/videos/esmo-2020-highlights-on-alpelisib-plus-fulvestrant-for-hr-her2-abc-the-solar-1-study_20200922161251.png)
- Date : 19/09/2020
- 0 0
ESMO 2020 Highlights on sacituzumab govitecan in metastatic TNBC: The ASCENT study
![ESMO 2020 Highlights on sacituzumab govitecan in metastatic TNBC: The ASCENT study ESMO 2020 Highlights on sacituzumab govitecan in metastatic TNBC: The ASCENT study](/images/videos/esmo-2020-highlights-on-sacituzumab-govitecan-in-metastatic-tnbc-the-ascent-study_20200922161302.png)
- Date : 19/09/2020
- 0 0
ESMO 2020 Highlights on pembrolizumab in LA-HNSCC: The GORTEC 2015-01 PembroRad study
![ESMO 2020 Highlights on pembrolizumab in LA-HNSCC: The GORTEC 2015-01 PembroRad study ESMO 2020 Highlights on pembrolizumab in LA-HNSCC: The GORTEC 2015-01 PembroRad study](/images/videos/esmo-2020-highlights-on-pembrolizumab-in-la-hnscc-the-gortec-2015-01-pembrorad-study_20200922161314.png)
- Date : 19/09/2020
- 0 0
4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma
![4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma 4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma](/images/videos/4-year-results-from-checkmate-238-adjuvant-nivo-vs-ipi-in-resected-stage-iii-iv-melanoma_20210303104436.png)
- Date : 21/09/2020
- 0 0
Adolescents, young adults and parents of children with cancer: supportive care
![Adolescents, young adults and parents of children with cancer: supportive care Adolescents, young adults and parents of children with cancer: supportive care](/images/videos/adolescents-young-adults-and-parents-of-children-with-cancer-supportive-care_20210303104824.png)
- Date : 21/09/2020
- 0 0
Ovarian cancer Phase III trial updates: IMagyn050/GOG 3015/ENGOT-OV39 and ICON8
![Ovarian cancer Phase III trial updates: IMagyn050/GOG 3015/ENGOT-OV39 and ICON8 Ovarian cancer Phase III trial updates: IMagyn050/GOG 3015/ENGOT-OV39 and ICON8](/images/videos/ovarian-cancer-phase-iii-trial-updates-imagyn050-gog-3015-engot-ov39-and-icon8_20210303104938.png)
- Date : 21/09/2020
- 0 0
SECOMBIT: sequencing of targeted agents/immunomodulatory Abs in metastatic BRAFV600-mutated melanoma
![SECOMBIT: sequencing of targeted agents/immunomodulatory Abs in metastatic BRAFV600-mutated melanoma SECOMBIT: sequencing of targeted agents/immunomodulatory Abs in metastatic BRAFV600-mutated melanoma](/images/videos/secombit-sequencing-of-targeted-agents-immunomodulatory-abs-in-metastatic-brafv600-mutated-melanoma_20210303105218.png)
- Date : 21/09/2020
- 0 0
Promising new treatments for sarcomas: immunotherapy and fusion targeted compounds
![Promising new treatments for sarcomas: immunotherapy and fusion targeted compounds Promising new treatments for sarcomas: immunotherapy and fusion targeted compounds](/images/videos/promising-new-treatments-for-sarcomas-immunotherapy-and-fusion-targeted-compounds_20210303105251.png)
- Date : 21/09/2020
- 0 0
ISG/OS-2 trial: amending treatment of methotrexate for non metastatic osteosarcoma
![ISG/OS-2 trial: amending treatment of methotrexate for non metastatic osteosarcoma ISG/OS-2 trial: amending treatment of methotrexate for non metastatic osteosarcoma](/images/videos/isg-os-2-trial-amending-treatment-of-methotrexate-for-non-metastatic-osteosarcoma_20210303105302.png)
- Date : 21/09/2020
- 0 0
Nivolumab for perioperative esophageal and gastroesophageal cancer: CheckMate-577
![Nivolumab for perioperative esophageal and gastroesophageal cancer: CheckMate-577 Nivolumab for perioperative esophageal and gastroesophageal cancer: CheckMate-577](/images/videos/nivolumab-for-perioperative-esophageal-and-gastroesophageal-cancer-checkmate-577_20210303105323.png)
- Date : 21/09/2020
- 0 0
ENGOT-EN3-NSGO/PALEO: Letrozole-palbociclib combination for endometrial cancer
![ENGOT-EN3-NSGO/PALEO: Letrozole-palbociclib combination for endometrial cancer ENGOT-EN3-NSGO/PALEO: Letrozole-palbociclib combination for endometrial cancer](/images/videos/engot-en3-nsgo-paleo-letrozole-palbociclib-combination-for-endometrial-cancer_20210303105406.png)
- Date : 21/09/2020
- 0 0
EPIC-OPC: testing for only p16 can lead to oropharyngeal cancer misclassification
![EPIC-OPC: testing for only p16 can lead to oropharyngeal cancer misclassification EPIC-OPC: testing for only p16 can lead to oropharyngeal cancer misclassification](/images/videos/epic-opc-testing-for-only-p16-can-lead-to-oropharyngeal-cancer-misclassification_20210303105429.png)
- Date : 21/09/2020
- 0 0
Nursing aspects on the transformation of cancer care during the Covid-19 pandemic
![Nursing aspects on the transformation of cancer care during the Covid-19 pandemic Nursing aspects on the transformation of cancer care during the Covid-19 pandemic](/images/videos/nursing-aspects-on-the-transformation-of-cancer-care-during-the-covid-19-pandemic_20210303105620.png)
- Date : 21/09/2020
- 0 0
Sacituzumab govitecan in metastatic urothelial carcinoma: updates on the Phase II study
![Sacituzumab govitecan in metastatic urothelial carcinoma: updates on the Phase II study Sacituzumab govitecan in metastatic urothelial carcinoma: updates on the Phase II study](/images/videos/sacituzumab-govitecan-in-metastatic-urothelial-carcinoma-updates-on-the-phase-ii-study_20210303110156.png)
- Date : 21/09/2020
- 0 0
Impact of biological sex on incidence, pathology and treatment responses to cancer
![Impact of biological sex on incidence, pathology and treatment responses to cancer Impact of biological sex on incidence, pathology and treatment responses to cancer](/images/videos/impact-of-biological-sex-on-incidence-pathology-and-treatment-responses-to-cancer_20210303110231.png)
- Date : 21/09/2020
- 0 0
Designing Phase II trials for LMS using PFS as primary endpoint: a STBSG meta-analysis
![Designing Phase II trials for LMS using PFS as primary endpoint: a STBSG meta-analysis Designing Phase II trials for LMS using PFS as primary endpoint: a STBSG meta-analysis](/images/videos/designing-phase-ii-trials-for-lms-using-pfs-as-primary-endpoint-a-stbsg-meta-analysis_20210303110252.png)
- Date : 21/09/2020
- 0 0
Patient and occupational safety in Europe: A survey by the European Oncology Nursing Society
![Patient and occupational safety in Europe: A survey by the European Oncology Nursing Society Patient and occupational safety in Europe: A survey by the European Oncology Nursing Society](/images/videos/patient-and-occupational-safety-in-europe-a-survey-by-the-european-oncology-nursing-society_20210303110329.png)
- Date : 21/09/2020
- 0 0
IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC
![IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC](/images/videos/imvigor130-patient-reported-outcomes-by-the-addition-of-atezolizumab-to-pbc-in-muc_20210303110413.png)
- Date : 21/09/2020
- 0 0
Sélection de congrès
14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024
![14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024](/images/conferences/14-mes-journ-es-des-r-f-rentiels-en-soins-oncologiques-de-support-afsos-2024_medium.png)
- Date : 12/12/2024
-
187
0
45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024
![45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024](/images/conferences/45emes-journ-es-de-la-soci-t-fran-aise-de-s-nologie-et-de-pathologie-mammaire-sfspm-2024_medium.jpeg)
- Date : 06/11/2024
-
830
0